Autologous and allogenic use of Stromal Vascular Fraction (SVF) and Decellularized Extracellular Matrices (ECM)
Submission Deadline: 30 Sep 2021
Guest Editor

Associate Professor of Plastic Surgery, University "Tor Vergata", Rome, Italy
Interests: Adipose stem cells; Stromal vascular fraction; Platelet rich plasma; Growth factors; Fat graft; Platelet rich lipotransfert; Fat tissue; Regenerative surgery; Regenerative medicine; Plastic surgery
Special Issue Information
Dear Colleagues,
Adipose-derived Mesenchymal Stem Cells (AD-MSCs), and Stromal vascular Fraction (SVF) in which they are contained, are cell-based therapy strategies to improve tissue regeneration or to repair tissue defects. In particular, Stem Cells (Mesenchymal and Follicular), Biotechnology and Bioactive Molecules (Platelet-Rich Plasma (PRP), Micrografts), and Stromal vascular Fraction may be helpful in this field.
In light of current knowledge on Mesenchymal Stem Cells (MSCs), AD-MSCs, epithelial and dermal cells, Human Follicle Mesenchymal Stem Cells (HF-MSCs), and Stromal Vascular Fraction (SVF), numerous researchers have developed different strategies to improve the effects of these varied biotechnology applications.
This Special Issue aims to collect multidisciplinary submissions of original research articles that demonstrate basic research and clinical impacts of autologous and/or allogeneic MSCs, AD-MSCs, and SVFs in tissue repair. Review articles that describe the current state of the art are also welcomed.
Potential topics include but are not limited to:
• The molecular mechanisms of SVF, AD-MSCs and MSCs during regeneration;
• Therapeutic application of SVF, AD-MSCs and MSCs (allogeneic and autologous) for major diseases and clinical conditions such as regenerative plastic surgery;
• MSCs and engineered MSCs as vehicles for drug delivery.
Dr. Pietro Gentile
Guest Editor
Keywords
- Autologous Stromal Vascular Fraction
- Allogeneic Stromal Vascular Fraction
- Autologous Adipose-Derived Mesenchymal Stem Cells
- Allogeneic Adipose-Derived Mesenchymal Stem Cells
- Allogeneic and autologous Mesenchymal Stem Cells
Manuscript Submission Information
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted manuscripts should be well formatted in good English.
Published Papers (2)
Bio-3D printing of scaffold-free osteogenic and chondrogenic constructs using rat adipose-derived stromal cells
Front. Biosci. (Landmark Ed) 2022, 27(2), 52; https://doi.org/10.31083/j.fbl2702052
(This article belongs to the Special Issue Autologous and allogenic use of Stromal Vascular Fraction (SVF) and Decellularized Extracellular Matrices (ECM))
A phase II clinical trial with repeated intrathecal injections of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis
Front. Biosci. (Landmark Ed) 2021, 26(10), 693–706; https://doi.org/10.52586/4980
(This article belongs to the Special Issue Autologous and allogenic use of Stromal Vascular Fraction (SVF) and Decellularized Extracellular Matrices (ECM))
